Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

NCT04100434 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

Interventions

DRUG: Evolocumab

Sponsor

Tianjin Chest Hospital